Coherent Biopharma is a biotechnology company that develops Bi-XDC technology to transform undruggable molecules and targets into druggable entities. The company focuses on addressing unmet medical needs in cancer and other areas.

Coherent Biopharma

Established in 2016, Coherent Biopharma’s proprietary bi-targeting XDC technology platform includes BESTTM Platform, C-PROTAC Platform and Chronic Diseases Platform. With the possibility to actively and cell/tissue specifically deliver any bioactive molecule, bi-targeting XDC technology of CBP has the potential to overcome the undruggability obstacle of a variety of molecules with high bioactivity, thus to Drug the Undruggable, and pioneer a new pathway of drug development.

COHERENT BIOPHARMA

IPhone / Mobile Compatible

Viewport Meta

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

WordPress

Global Site Tag

Robert Huang

Founder and CEO

Biopharma Startups

China Startups (Top 10K)

Biopharma Companies

Jiangsu Startups Founded in 2016

Coherent Biopharma is a pahrmaceutical based agency.

Shengdi Investment

Series B - Coherent Biopharma

Huimei Capital

6 Dimensions Capital

Series A - Coherent Biopharma

Frontline BioVentures

Suzhou

Jiangsu

China

Asia

Next Generation Drug Conjugates Market to Soar with Over 20 ...

Conjugation and Labeling Services Industry Outlook to 2035 ...

Coherent Biopharma nets $100M in financing for Bi-XDC drugs

Coherent Biopharma patents new peptide-drug conjugates

A platform that transforms undruggable molecules into druggable entities, targeting substantial unmet medical needs in cancer and beyond.

A dual-targeted drug conjugate developed using Bi-XDC technology, targeting FRα and TRPV6 receptors with MMAE as the payload, showing efficacy in ovarian and breast cancer.

A bi-specific ligand conjugated molecule targeting FRα and PSMA receptors, incorporating an optimized bi-ligand system and an enzyme-cleavable trifunctional linker with a cytotoxin MMAE payload.

A second-generation bi-specific ligand conjugated compound targeting FRα/TRPV6 receptors with a topoisomerase 1 inhibitor derivative payload, designed for improved stability and efficacy in various cancers.

A versatile technology platform for high-throughput discovery and screening of bi-specific ligand systems, providing the required bi-ligands.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 26, 2024 9:48 AM	1a420c3e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	b21829bd
crunchbase profile	general	Dec 4, 2024 1:32 PM	20e7a861
li profile	general	Aug 26, 2024 9:48 AM	f522117e
translate crunchbase fundingrounds	general	Dec 4, 2024 1:59 PM	b7f2e576
peers	general	Aug 26, 2024 9:48 AM	4a124c8f
news basic	general	Aug 26, 2024 9:48 AM	711d7cfc
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COHE

COM:COHERENTBIO

Coherent Biopharma